These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
152 related articles for article (PubMed ID: 12471654)
21. A randomized two-by-two comparison of high-dose bolus tirofiban versus abciximab and unfractionated heparin versus bivalirudin during percutaneous coronary revascularization and stent placement: the tirofiban evaluation of novel dosing versus abciximab with clopidogrel and inhibition of thrombin (TENACITY) study trial. Moliterno DJ; Catheter Cardiovasc Interv; 2011 Jun; 77(7):1001-9. PubMed ID: 21598351 [TBL] [Abstract][Full Text] [Related]
22. Role of abciximab in the treatment of coronary artery disease. Gabriel HM; Oliveira EI Expert Opin Biol Ther; 2006 Sep; 6(9):935-42. PubMed ID: 16918260 [TBL] [Abstract][Full Text] [Related]
23. Use of glycoprotein IIb/IIIa inhibition plus fibrinolysis in acute myocardial infarction. Hudson MP; Greenbaum AB; Harrington RA; Ohman EM J Thromb Thrombolysis; 1999 Jun; 7(3):241-5. PubMed ID: 10373717 [TBL] [Abstract][Full Text] [Related]
24. Combination reperfusion therapy with abciximab and reduced dose reteplase: results from TIMI 14. The Thrombolysis in Myocardial Infarction (TIMI) 14 Investigators. Antman EM; Gibson CM; de Lemos JA; Giugliano RP; McCabe CH; Coussement P; Menown I; Nienaber CA; Rehders TC; Frey MJ; Van der Wieken R; Andresen D; Scherer J; Anderson K; Van de Werf F; Braunwald E Eur Heart J; 2000 Dec; 21(23):1944-53. PubMed ID: 11071800 [TBL] [Abstract][Full Text] [Related]
25. Thrombin generation and fibrinolytic activities among patients receiving reduced-dose alteplase plus abciximab or undergoing direct angioplasty plus abciximab for acute myocardial infarction. Mak KH; Lee LH; Wong A; Chan C; Koh TH; Lau KW; Lim YL Am J Cardiol; 2002 Apr; 89(8):930-6. PubMed ID: 11950430 [TBL] [Abstract][Full Text] [Related]
26. Spotlight on abciximab in patients with ischemic heart disease undergoing percutaneous coronary revascularization. Ibbotson T; McGavin JK; Goa KL Am J Cardiovasc Drugs; 2003; 3(5):381-6. PubMed ID: 14728074 [TBL] [Abstract][Full Text] [Related]
27. Administration of abciximab during percutaneous coronary intervention reduces both ex vivo platelet thrombus formation and fibrin deposition: implications for a potential anticoagulant effect of abciximab. Dangas G; Badimon JJ; Coller BS; Fallon JT; Sharma SK; Hayes RM; Meraj P; Ambrose JA; Marmur JD Arterioscler Thromb Vasc Biol; 1998 Aug; 18(8):1342-9. PubMed ID: 9714143 [TBL] [Abstract][Full Text] [Related]
28. Intracoronary versus intravenous abciximab bolus in patients with ST-segment elevation myocardial infarction: 1-year results of the randomized AIDA STEMI trial. Desch S; Wöhrle J; Hambrecht R; Rittger H; Birkemeyer R; Lauer B; Neuhaus P; Brosteanu O; Sick P; Pauschinger M; Kerber S; Kleinertz K; de Waha S; Eitel I; Schuler G; Thiele H J Am Coll Cardiol; 2013 Sep; 62(13):1214-5. PubMed ID: 23850911 [No Abstract] [Full Text] [Related]